A Phase 4 interventional study of Remimazolam besylate + propofol MCT and Propofol MCT in Neurologic Disorder, sponsored by Chung-Ang University Gwangmyeong Hospital. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.
Sponsored by Chung-Ang University Gwangmyeong Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to compare total intravenous anesthetic agents: combined remimazolam and propofol vs. propofol monotherapy. The comparison parameters are intraoperative hypotension, patient's involuntary movement, neurophysiological monitoring quality, onset time, recovery time, and postoperative rescue anti-emetics requirements.
This study hypothesizes that the combination regimen of remimazolam and propofol as total intravenous anesthesia in neurosurgical procedures requiring neurophysiological monitoring can reduce the incidence of hypotension compared to propofol monotherapy while providing comparable levels of neurophysiological monitoring and surgical conditions. With this hypothesis, the study aims to compare the frequency, severity, and duration of hypotension, frequency of patient movement, and appropriateness of neurophysiological monitoring between the combination therapy of remimazolam and propofol and propofol monotherapy in total intravenous anesthesia.
759 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.
This study's planned enrollment of 56 is close to the median of 55 across 496 interventional studies indexed under Nervous System Diseases.
Browse Nervous System Diseases studies →Chung-Ang University Gwangmyeong Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination regimen (remimazolam plus propofol)
Drug: Remimazolam besylate + propofol MCT
Propofol monotherapy
Drug: Propofol MCT
Drug pages: Remimazolam besilateStudies of Remimazolam besilateRemimazolam besilate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
Propofol MCT 2-8 mcg/ml using target-controlled infusion
Incidence of intraoperative hypotension
mean arterial pressure \< 65mmHg
Time frame: operation day - postoperative 1 day
Amount and number of inotropic agents
intraoperative inotropics amount (phenylephrine(mcg), ephedrine(mg), norepinephrine(mcg), dopamine(mg))
Time frame: operation day - postoperative 1 day
Incidence of participants' intraoperative involuntary movement
number of patients involuntary movement during operation (ex. no movement:0 , 3 times of movement: 3)
Time frame: operation day - postoperative 1 day
scores of neurophysiologic monitoring quality
0-5 scale of neurophysiologic monitoring quality, scored by neurophysiologic monitoring technologist (poor: 0, good: 5)
Time frame: operation day - postoperative 1 day
onset time of study drugs
time from administration of study drugs(remimazolam+propofol or propofol) to Bispectral index value \< 60
Time frame: operation day - postoperative 1 day
The administration number of rescue anti-emetic agents
postoperative rescue anti-emetic agents (ramosetron, palonosetron, metoclopramide) requirements
Time frame: operation day - postoperative 3 day
Time-weighted average of intraoperative hypotension
(depth of hypotension in millimeters of mercury below a MAP of 65mmHg × time in minutes spent below a MAP of 65mmHg)÷total duration of operation in minutes
Time frame: operation day - postoperative 1 day
recovery time of study drugs (remimazolam+propofol or propofol)
time from discontinuation of study drugs(remimazolam+propofol or propofol) to Bispectral index value \> 60
Time frame: operation day - postoperative 1 day
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2024; primary completion for May 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Remimazolam besilate · Propofol
Chung-Ang University Gwangmyeong Hospital